Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib 1.5% Cream in Early Stage Hidradenitis Suppurativa
NCT04414514Phase 2Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib cream in hidradenitis suppurativa (HS), sponsored by Penn State Health Milton S. Hershey Medical Center. Started Oct 2022; status: terminated.
02
Drugs
ruxolitinib cream
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04414514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414514.